The Chemical Biology Core Facility (CBCF) offers the infrastructure and expertise for assay development, small-molecule screening and use of medicinal chemistry to optimise compounds against novel targets for ‘biotool’ or early drug development.
The facility is set up as a collaboration between EMBL and German Cancer Research Center (DKFZ) to provide the infrastructure and expertise to open up small molecule development to research groups at these institutions.
|Major achievements and accomplishments|
|2004||Facility established in 2004 as a collaboration between EMBL and German Cancer Research Center (DKFZ).|
|2006||Spin-off of Elara Pharmaceuticals GmbH out of the facility to develop dual inhibitors targeting tumors.|
|2009||Computational chemistry established. Spin-off of Savira GmbH to develop and commercialise screening derived hits targeting influenza virus.|
|2013||Upgrade of the P3 Evolution pipetting system to an automation platform linking the Janus robot, liquid handler, Cytomat cell incubator and Envision reader|
|2014||Medicinal Chemistry lab opened|
|2015||Execution of 1536 HTS screen with patient derived cells on automation platform|
The overall direction of the facility is overseen by a steering committee which has senior members of staff from the EMBL and DKFZ. The projects are considered on a case-by-case basis, following preliminary evaluation for suitability and amenability to screening. The committee further reviews and assesses technical difficulties and determines priorities for new projects.
Please contact us to submit a project proposal.
Chemical Biology Core Facility
EMBL Heidelberg, Meyerhofstraße 1, 69117 Heidelberg, Germany
Phone: +49 6221 387-8303
Fax: +49 6221 387-8306
Email: General enquiries